Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783181 · ClinicalTrials.gov registry record · Phase 1
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
A Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by Adrenas Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT04783181: Active Phase 1 study of Congenital Adrenal Hyperplasia, sponsored by Adrenas Therapeutics.
NCT04783181 is a Phase 1 study of Congenital Adrenal Hyperplasia that is active but no longer recruiting, run by Adrenas Therapeutics. The registered enrollment target is 8 participants, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04783181, a Phase 1 study of Congenital Adrenal Hyperplasia, is active but no longer recruiting, sponsored by Adrenas Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
Conditions Studied
Interventions
- BIOLOGICAL AAV BBP-631
Study Locations (5)
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- National Institutes of Health Clinical Center - Bethesda
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Lucas Research, Inc. - Morehead City
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What the registry record for NCT04783181 still lists
NCT04783181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 101-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which AAV BBP-631 is the first listed.
NCT04783181 lists 5 locations in 5 states (Illinois, Maryland, Minnesota).
Frequently Asked Questions
What is clinical trial NCT04783181 about?
NCT04783181 is a clinical study titled "A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)". This study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
What is the current status of trial NCT04783181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-07-01. Estimated completion is 2029-02.
What conditions does trial NCT04783181 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT04783181?
The interventions under investigation include: AAV BBP-631 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04783181?
This trial is sponsored by Adrenas Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04783181 being conducted?
This trial has 5 study locations across Illinois, Maryland, Minnesota, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04783181's enrollment target sits among peer trials
8 9th of 8 the lowest of 8 other Congenital Adrenal Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Adrenal Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
COMPLETED · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
RECRUITING · Phase 2
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI